



**BAL PHARMA LIMITED**

CIN L85110KA1987PLC008368

Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099  
 Phone : 91 80 41379500 Fax : 91 80 222354057 email: secretarial@balpharma.com url: www.balpharma.com  
**STANDALONE&CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2015**

(In Rs Lakhs)

Sr. No:	Particulars	STANDALONE				CONSOLIDATED	
		Quarter Ended		Year Ended		Year Ended	
		Audited	Unaudited	Audited	Audited	Audited	Audited
<b>PART I</b>							
<b>1</b>	<b>Income from Operations</b>						
a)	Net Sales/Income from operations (Net of Excise Duty)	4,993.90	4,222.25	4,662.07	18,245.70	17,341.40	18,248.43
b)	Other Operating Income	209.83	72.02	245.14	467.30	545.80	467.30
	<b>Total Income from Operations (net)</b>	<b>5,203.73</b>	<b>4,294.27</b>	<b>4,907.21</b>	<b>18,713.00</b>	<b>17,887.20</b>	<b>18,715.73</b>
<b>2</b>	<b>Expenses</b>						
a)	Consumption of Raw Materials/ Packing Material	2,675.88	2,221.59	2,435.20	9,611.71	8,911.84	9,611.71
b)	Purchase of Stock in Trade	216.41	116.09	144.04	622.89	515.41	627.69
c)	Increase/decrease in stock in trade and WIP	(128.74)	(91.00)	107.07	(314.68)	95.94	(319.03)
d)	Employee Cost	834.60	787.20	744.86	3,196.24	2,812.36	3,224.27
e)	Depreciation and amortisation expenses	357.69	115.85	101.72	700.35	473.97	702.33
f)	Other Expenditure	1,108.76	883.15	1,035.27	3,844.23	3,763.97	3,860.48
g)	<b>Total</b>	<b>5,064.60</b>	<b>4,032.88</b>	<b>4,568.16</b>	<b>17,660.74</b>	<b>16,573.49</b>	<b>17,707.45</b>
<b>3</b>	<b>Profit from Operations before other Income, finance costs and Exceptional Items(1-2)</b>	<b>139.13</b>	<b>261.39</b>	<b>339.05</b>	<b>1,052.26</b>	<b>1,313.71</b>	<b>1,008.28</b>
<b>4</b>	<b>Other Income</b>	<b>69.39</b>	<b>1.02</b>	<b>37.20</b>	<b>119.48</b>	<b>64.63</b>	<b>117.41</b>
<b>5</b>	<b>Profit before finance cost and Exceptional Items (3+4)</b>	<b>208.52</b>	<b>262.41</b>	<b>376.24</b>	<b>1,171.74</b>	<b>1,378.34</b>	<b>1,125.69</b>
<b>6</b>	<b>Finance Costs</b>	<b>144.49</b>	<b>158.23</b>	<b>181.85</b>	<b>651.62</b>	<b>715.74</b>	<b>651.64</b>
<b>7</b>	<b>Profit after finance cost but before Exceptional items</b>	<b>64.03</b>	<b>104.18</b>	<b>194.40</b>	<b>520.12</b>	<b>662.60</b>	<b>474.05</b>
<b>8</b>	<b>Exceptional items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Profit/Loss from ordinary activities Before Tax ( 7-8)</b>	<b>64.03</b>	<b>104.18</b>	<b>194.40</b>	<b>520.12</b>	<b>662.60</b>	<b>474.05</b>
<b>10</b>	<b>Tax expenses</b>	<b>8.36</b>	<b>25.76</b>	<b>58.63</b>	<b>117.84</b>	<b>155.37</b>	<b>118.74</b>
<b>11</b>	<b>Net Profit /Loss from ordinary Activities after Tax</b>	<b>55.67</b>	<b>78.41</b>	<b>135.76</b>	<b>402.28</b>	<b>507.23</b>	<b>355.31</b>
<b>12</b>	<b>Extra ordinary items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Net Profit / Loss for the period</b>	<b>55.67</b>	<b>78.41</b>	<b>135.76</b>	<b>402.28</b>	<b>507.23</b>	<b>355.31</b>
<b>14</b>	<b>Minority interest</b>						<b>(7.48)</b>
<b>15</b>	<b>Net Profit / Loss after taxes and minority interest</b>	<b>55.67</b>	<b>78.41</b>	<b>135.76</b>	<b>402.28</b>	<b>507.23</b>	<b>362.79</b>
<b>14</b>	<b>Paid-up Equity Share capital( face value of Rs 10 each )</b>	<b>1,287.24</b>	<b>1,287.24</b>	<b>1,111.14</b>	<b>1,287.24</b>	<b>1,111.14</b>	<b>1,291.24</b>
<b>15</b>	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>					<b>3,283.79</b>	<b>3,283.79</b>
<b>16</b>	<b>Earnings Per Share (of Rs 10 each) (Quarterly EPS not annualised)</b>						
a)	Basic	<b>0.43</b>	<b>0.81</b>	<b>1.25</b>	<b>3.14</b>	<b>4.77</b>	<b>2.83</b>
b)	Diluted	<b>0.43</b>	<b>0.81</b>	<b>1.21</b>	<b>3.11</b>	<b>4.60</b>	<b>2.80</b>
<b>PART II</b>							
<b>A</b>	<b>Particulars of Shareholding</b>						
<b>1)</b>	<b>Public shareholding</b>						
	- Number of Shares	65,86,570	65,86,570	51,42,086	65,86,570	51,42,086	65,86,570
	- Percentage of shareholding	51.17	51.17	46.28	51.17	46.28	51.17
<b>2)</b>	<b>Promoters &amp; Promoter group Shareholding</b>						
<b>a)</b>	<b>Pledged / Encumbered</b>						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-	-
<b>b)</b>	<b>Non-encumbered</b>						
	- Number of Shares	62,85,802	62,85,802	59,69,302	62,85,802	59,69,302	62,85,802
	- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shareholding (as a % of total share capital of the company)	48.83	48.83	53.72	48.83	53.72	48.83

## PART III

B Investor Complaints		Quarter ended 31.03.2015
Pending at the beginning of the quarter		-
Received during the quarter		11
Disposed of during the quarter		11
Remaining unresolved at the end of the quarter		-

## Notes:

1 Statement of assets and liabilities as on

(Rs Lakhs)

Particulars	STANDALONE		CONSOLIDATED	
	31.03.2015	31.03.2014	31.03.2015	31.03.2014
Share Capital	1,287.24	1,111.14	1,291.24	1,111.14
Reserves & Surplus	4,070.99	3,720.18	4,031.50	3,720.18
Non Controlling interest	-	-	(7.48)	-
Money received against share warrant	201.50	173.64	201.50	173.64
	<b>5,559.73</b>	<b>5,004.96</b>	<b>5,516.75</b>	<b>5,004.96</b>
<b>Non Current Liabilities</b>				
Long-term borrowings	664.43	797.01	664.43	797.01
Deferred tax liabilities (Net)	728.58	823.72	729.48	823.72
Other long term liabilities	74.59	65.59	74.59	65.59
Long-term provisions	165.19	105.98	165.18	105.98
	<b>1,632.79</b>	<b>1,792.30</b>	<b>1,633.69</b>	<b>1,792.30</b>
<b>Current liabilities</b>				
Short- term borrowings	4,013.79	4,274.99	4,013.79	4,274.99
Trade payables	3,848.65	3,353.09	3,853.49	3,353.09
Other current liabilities	1,177.11	865.93	1,185.74	865.93
Short- term provisions	182.82	183.14	182.82	183.14
	<b>9,222.37</b>	<b>8,677.15</b>	<b>9,235.84</b>	<b>8,677.15</b>
<b>TOTAL</b>	<b>16,414.89</b>	<b>15,474.41</b>	<b>16,386.28</b>	<b>15,474.41</b>
<b>Non- current assets</b>				
Fixed Assets	5,267.29	5,542.47	5,296.51	5,542.47
Non- current investments	109.50	1.50	1.50	1.50
Long term loans and advances	540.41	396.43	542.88	396.43
Other non-current assets	32.95	22.36	32.95	22.36
	<b>5,950.15</b>	<b>5,962.76</b>	<b>5,873.84</b>	<b>5,962.76</b>
<b>Current assets</b>				
Inventories	3,577.17	3,171.42	3,581.52	3,171.42
Trade receivables	4,498.76	4,548.82	4,498.49	4,548.82
Cash and cash equivalents	453.80	302.42	549.44	302.42
Short-term loans and advances	1,915.07	1,476.20	1,863.06	1,476.20
Other current assets	19.94	12.80	19.94	12.80
	<b>10,464.74</b>	<b>9,511.65</b>	<b>10,512.45</b>	<b>9,511.65</b>
<b>TOTAL</b>	<b>16,414.89</b>	<b>15,474.41</b>	<b>16,386.28</b>	<b>15,474.41</b>

2 The above audited financial results as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 29.05.2015.

3 The figures for the last quarter are the balancing figures between the audited figures in respect of the full financial year and the year to date figures up to the third quarter of the financial for the current year and for the previous year.

4 Effective from 1 April 2014, the company has changed the depreciation charge based on revised remaining useful life of the assets as per the requirement of schedule II of the Companies Act 2013. Due to this the depreciation charges for the last 12 months period ended on March 31, 2015 is higher by Rs 173.27 lacs. Further based on transitional provisions as provided in schedule II, an amount of Rs 70.11 lacs (net of deferred tax) has been charged to the accumulated retained earnings (surplus) in respect of assets whose useful life is nil as at April 1, 2014. This additional provision for depreciation had its impact on profits of the Company.

5 The Board has recommended a dividend of Re.1 per equity share of Rs.10 each, for the F.Y 14.15.

6 During the year under review, the company through its subsidiary i.e. Lifezen Healthcare Pvt Ltd has entered into Over The Counter (OTC) segment of business.

7 Consolidated financial results includes the results of subsidiaries i.e. Lifezen Healthcare Pvt Ltd and Balance Clinics LLP, which were incorporated during the FY 2014-15

8 Previous year figures were regrouped/rearranged to conform to the classification of current year.

9 As the company deals with single segment i. e pharmaceuticals, segment wise figures are not furnished.

By order of the Board of Directors  
For Bal Pharma limited

Bangalore

Shailesh Siroya  
Managing Director